SUNNYVALE, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced multiple presentations and published abstracts regarding its novel Bruton's tyrosine kinase (BTK) inhibitor and histone deacetylase (HDAC) inhibitor compounds. The presentations will take place at the American Society of Hematology (ASH) 49th Annual Meeting, in Atlanta, GA, December 8-11, 2007.
All abstracts are currently available online at http://www.abstracts2view.com/hem07, and appear in the November 16, 2007 issue of Blood, The Journal of The American Society of Hematology.
About Pharmacyclics
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with whole brain radiation therapy for treatment of brain metastases from non-small cell lung cancer was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.
CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or Carolyn
Bumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,
Inc.
Web site: http://www.pharmacyclics.com/
